Influence of hyperuricemia on long-term renal allograft function after renal transplantation* is it a factor of chronic renal allograft dysfunction?

Journal of Clinical Rehabilitative Tissue Engineering Research

Volumn 14, Issue 5, 2010, Pages 923-927

  Zou, Gui Mian ^a   Sui, Wei Guo ^a   Yan, Qiang ^a   Che, Wen Ti ^a   Chen, Huai Zhou ^a   Zou, He Qun ^b  

^a The 181th Hospital of PLA   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYCLOSPORIN; MIZORIBINE; PREDNISONE; URIC ACID;

ADULT; ARTICLE; CHINA; CHRONIC ALLOGRAFT NEPHROPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT SURVIVAL; HOSPITAL ADMISSION; HUMAN; HYPERURICEMIA; KIDNEY ALLOGRAFT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; RISK FACTOR; URIC ACID BLOOD LEVEL;

EID: 77955007334     PISSN: 16738225     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1673-8225.2010.05.040     Document Type: Article

References (31)

1. Becker MA, Jolly M. Hyperuricemia and associated diseases. Rheum Dis Clin North Am. 2006;32(2):275-293.
2. Nakagawa T, Mazzali M, Kang DH, et al. Uric acid-a uremic toxin? Blood Purif. 2006;24(1):67-70.
3. Abbott KC, Kimmel PL, Dharnidharka V, et al. New-onset gout after kidney transplantation: incidence, risk factors and implications. Transplantation. 2005;80(10):1383-1391.
4. Chonchol M, Shlipak MG, Katz R, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis. 2007;50(2):239-247.
5. Min SI, Yun IJ, Kang JM, et al. Moderate-to-severe early-onset hyperuricaemia: a prognostic marker of long-term kidney transplant outcome. Nephrol Dial Transplant. 2009;24(8):2584-2590.
6. Akgul A, Bilgic A, Ibis A, et al. Is uric acid a predictive factor for graft dysfunction in renal transplant recipients? Transplant Proc. 2007;39(4):1023-1026.
7. Collins AJ, Foley R, Herzog C, et al. Excerpts from the United States Renal Data System 2007 annual data report. Am J Kidney Dis. 2008;51(1 Suppl 1): S1-320.
8. Stamp L, Ha L, Searle M, et al. Gout in renal transplant recipients. Nephrology (Carlton). 2006;11(4):367-371.
9. Akalin E, Ganeshan SV, Winston J, et al. Hyperuricemia is associated with the development of the composite outcomes of new cardiovascular events and chronic allograft nephropathy. Transplantation. 2008;86(5):652-658.
10. Stypinski D, Obaidi M, Combs M, et al. Safety, tolerability and pharmacokinetics of higher-dose mizoribine in healthy male volunteers. Br J Clin Pharmacol. 2007;63(4):459-468.
11. Stamp L, Searle M, O'Donnell J, et al. Gout in solid organ transplantation: a challenging clinical problem. Drugs. 2005;65(18):2593-2611.
12. Hernandez-Molina G, Cachafeiro-Vilar A, Villa AR, et al. Gout in renal allograft recipients according to the pretransplant hyperuricemic status. Transplantation. 2008;86(11):1543-1547.
13. Cohen SD, Kimmel PL, Neff R, et al. Association of incident gout and mortality in dialysis patients. J Am Soc Nephrol. 2008;19(11):2204-2210.
14. Nan H, Qiao Q, Dong Y, et al. The prevalence of hyperuricemia in a population of the coastal city of Qingdao, China. J Rheumatol. 2006;33(7):1346-1350.
15. Mellen PB, Bleyer AJ, Erlinger TP, et al. Serum uric acid predicts incident hypertension in a biethnic cohort: the atherosclerosis risk in communities study. Hypertension. 2006;48(6):1037-1042.
16. Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. Hypertension. 2003;42(3):247-252.
17. Corry DB, Tuck ML. Uric acid and the vasculature. Curr Hypertens Rep. 2006;8(2):116-119.
18. Zou H. Tubulointerstitial Nephropathy. 1st ed. Xi'an: The Fourth Millitary Medical University Publishing Company. 2006;159-167.
19. Sanchez-Lozada LG, Nakagawa T, Kang DH, et al. Hormonal and cytokine effects of uric acid. Curr Opin Nephrol Hypertens. 2006;15(1):30-33.
20. Song E, Zou H, Yao Y, et al. Early application of Met-RANTES ameliorates chronic allograft nephropathy. Kidney Int. 2002;61(2):676-685.
21. Gersch MS, Johnson RJ. Uric acid and the immune response. Nephrol Dial Transplant. 2006;21(11):3046-3047.
22. Hu DE, Moore AM, Thomsen LL, et al. Uric acid promotes tumor immune rejection. Cancer Res. 2004;64(15):5059-5062.
23. Sui X, Church TS, Meriwether RA, et al. Uric acid and the development of metabolic syndrome in women and men. Metabolism. 2008;57(6):845-852.
24. Kawamoto R, Tomita H, Oka Y, et al. Relationship between serum uric acid concentration, metabolic syndrome and carotid atherosclerosis. Intern Med. 2006;45(9):605-614.
25. Puig JG, Martinez MA. Hyperuricemia, gout and the metabolic syndrome. Curr Opin Rheumatol. 2008;20(2):187-191.
26. Sui W, Zou H, Zou G, et al. Clinical study of the risk factors of insulin resistance and metabolic syndrome after kidney transplantation. Transpl Immunol. 2008;20(1-2): 95-98.
27. Chen LK, Lin MH, Lai HY, et al. Uric acid: a surrogate of insulin resistance in older women. Maturitas. 2008;59(1):55-61.
28. Neogi T. Asymptomatic hyperuricemia: perhaps not so benign? J Rheumatol. 2008;35(5):734-737.
29. Milionis HJ, Kakafika AI, Tsouli SG, et al. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J. 2004;148(4):635-640.
30. Ka T, Inokuchi T, Tsutsumi Z, et al. Effects of a fenofibrate/losartan combination on the plasma concentration and urinary excretion of purine bases. Int J Clin Pharmacol Ther. 2006;44(1):22-26. (Pubitemid 43090676)
31. Madero M, Sarnak MJ, Wang X, et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis. 2009;53(5):796-803.